Nogapendekin alfa inbakicept is a first-in-class interleukin 15 (IL-15) receptor agonist that results in the proliferation of killer T-cells to attack cancer.
Nogapendekin alfa inbakicept is indicated for treatment with Bacillus Calmette-Guérin (BCG) for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.